These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10758014)

  • 21. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
    Sension MG
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current approaches to treatment for HIV-1 infection.
    Powderly WG
    J Neurovirol; 2000 May; 6 Suppl 1():S8-S13. PubMed ID: 10871760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART.
    Manfredi R; Chiodo F
    Infection; 2000; 28(3):167-70. PubMed ID: 10879643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinician's perspective: when to start antiretroviral treatment and when to change therapy.
    Montaner JS; Lange JM
    J Biol Regul Homeost Agents; 1995; 9(3):114-8. PubMed ID: 8782020
    [No Abstract]   [Full Text] [Related]  

  • 32. Overview of antiretroviral therapy.
    Coleman R
    Pharmacotherapy; 1994; 14(6 Pt 2):3S-8S. PubMed ID: 7533904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of combination antiretroviral therapy.
    Collier AC
    Adv Exp Med Biol; 1996; 394():355-72. PubMed ID: 8815701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Making sense of side effects.
    Cocohoba J
    BETA; 2011; 23(4):19-29. PubMed ID: 22567824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on adherence to HIV therapy.
    Eldred L; Cheever L
    Hopkins HIV Rep; 1998 Jan; 10(1):10-1. PubMed ID: 11365131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. German-Austrian guidelines for antiretroviral therapy of HIV infection. December 1997. Common statement of the Deutsche AIDS-Gesellschaft (DAIG) and Osterreichische AIDS-Gesellschaft (OAG).
    Eur J Med Res; 1997 Dec; 2(12):535-42. PubMed ID: 9498930
    [No Abstract]   [Full Text] [Related]  

  • 37. Strategies of antiretroviral therapy in adults.
    Itani S; Bartlett JA
    Urol Clin North Am; 1999 Nov; 26(4):809-20, ix-x. PubMed ID: 10584621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to protease inhibitors.
    Murri R; Ammassari A; Antinori A
    Ann Intern Med; 2001 Apr; 134(7):625. PubMed ID: 11281748
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral therapy: reverse transcriptase inhibition.
    Connolly KJ; Hammer SM
    Antimicrob Agents Chemother; 1992 Feb; 36(2):245-54. PubMed ID: 1376595
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of antiretroviral therapy in children and pregnant women.
    McKinney RE
    Adv Exp Med Biol; 1996; 394():345-54. PubMed ID: 8815700
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.